413 related articles for article (PubMed ID: 27486174)
21. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
22. c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
Musso L; Mazzini S; Rossini A; Castagnoli L; Scaglioni L; Artali R; Di Nicola M; Zunino F; Dallavalle S
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):615-629. PubMed ID: 29229300
[TBL] [Abstract][Full Text] [Related]
23. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
[TBL] [Abstract][Full Text] [Related]
24. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
25. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity.
Kim JK; Kim JY; Kim HJ; Park KG; Harris RA; Cho WJ; Lee JT; Lee IK
PLoS One; 2013; 8(11):e80391. PubMed ID: 24260381
[TBL] [Abstract][Full Text] [Related]
26. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
[TBL] [Abstract][Full Text] [Related]
27. Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells.
Padmanabhan A; Gosc EB; Bieberich CJ
J Cell Biochem; 2013 May; 114(5):1050-7. PubMed ID: 23129228
[TBL] [Abstract][Full Text] [Related]
28. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
29. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
[TBL] [Abstract][Full Text] [Related]
30. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
31. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
32. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
[TBL] [Abstract][Full Text] [Related]
33. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
[TBL] [Abstract][Full Text] [Related]
34. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.
Hald ØH; Olsen L; Gallo-Oller G; Elfman LHM; Løkke C; Kogner P; Sveinbjörnsson B; Flægstad T; Johnsen JI; Einvik C
Oncogene; 2019 Apr; 38(15):2800-2813. PubMed ID: 30542116
[TBL] [Abstract][Full Text] [Related]
36. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
37. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
Li K; Li Y; Zhou D; Fan Y; Guo H; Ma T; Wen J; Liu D; Zhao L
Bioorg Med Chem; 2016 Apr; 24(8):1889-97. PubMed ID: 26979485
[TBL] [Abstract][Full Text] [Related]
39. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
40. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]